Zacks.com on MSN3d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...
PharmExec4d
Phase III Trial Data Show Uplizna Significantly Improves Symptoms of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
PMLive4d
Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study
The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...
Nasdaq3d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.
pharmaphorum3d
Third indication beckons for Amgen's Uplizna
Amgen acquired CD19-directed antibody Uplizna (inebilizumab ... a significant improvement in myasthenia gravis activities of daily living (MG-ADL) disease scores at 26 weeks compared to placebo ...
Clinical Trials Arena on MSN1d
Immunovant will not seek approval for MG therapy, despite hitting endpoints
Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...